Sustained Virologic Response Clinical Trial
Official title:
The Response of Reducing Dose of Peginterferon Alfa-2a in Koreans With Chronic Hepatitis C Genotype 1; Randomized Controlled Multicenter Study 100% Versus 80%
1. Randomized controlled multicenter study
2. The response of reducing dose of peginterferon alfa-2a in Koreans with chronic
hepatitis C genotype 1
3. IL28B polymorphism in Koreans with CHC
The virologic response of Koreans to combination therapy for chronic hepatitis C is similar
to non-Asians; however, dose modification occurs more frequently in Koreans.
-When we evaluated the rates of peginterferon α-2a and ribavirin dose modifications and
their effect on the virologic response in Koreans, we suggested that using at least 80% of
the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side
effects during the entire treatment period and a lower dose of ribavirin may be as
efficacious as a standard dose(Korean J Intern Med 2009;24:203-211).
So we investigate whether the group of 80% use dosage of peginterferon alfa-2a did not show
inferior response rather than that of 100 % use dosage group and minimize the adverse
events.
There are recently reports that Koreans have favorable IL28B SNP for CHC treatment.
-We investigate the IL28B polymorphism in Koreans with CHC and this result can effect on the
SVR depending on the dosage of peginterferon alfa 2a
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03251690 -
Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression
|
N/A | |
| Recruiting |
NCT04724785 -
Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
|